Stifel Reiterates Buy on Ultragenyx (RARE), Results Suggest Stable and Growing Business, Pipeline Has Multiple Value Creation Opportunities
Tweet Send to a Friend
Stifel analyst Dae Gon Ha reiterated a Buy rating and $176.00 price target on Ultragenyx Pharma (NASDAQ: RARE), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
